GC Lab Cell and U.S. unit Artiva enter NK cell therapy deal with Merck

Minu Kim 2021. 1. 29. 10:30
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

South Korea’s GC Lab Cell and its U.S affiliate Artiva Biotherapeutics, Inc., have entered an exclusive collaboration and license deal with Merck, known as MSD outside North America, to develop two and one optional novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens.

Under the terms of the agreement, Artiva will receive a $30 million upfront payment for the first two programs and an additional $15 million payment if Merck exercises its option for a third program. Artiva is also eligible to receive future development and commercial milestones of up to $612 million per program and royalties payable by Merck on worldwide sales of any product derived from the collaboration. Merck agreed to provide research funding to Artiva for each of the programs under the collaboration.

GC Lab Cell separately reported in Seoul its upfront share of $15 million and up to $322.35 million per program on future development and commercial milestone.

GC Lab Cell shares jumped 6.83 percent to close Friday at 128,200 won ($114.6).

The Merck CAR-NK collaboration programs will leverage Artiva’s novel NK-specific CAR costimulatory structures and highly scaled, proprietary NK cell manufacturing platform. Artiva’s manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity, according to Artiva’s statement.

Artiva headquartered in San Diego was set up by GC Holdings and GC Lab Cell devoted to NK cell platform incorporating cell expansion, activation, and engineering technology developed GC LabCell. Shares of GC Holdings were also rose 7.8 percent to 48,350 won.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?